Medtronic's Rally Faces Valuation and Litigation Hurdles Despite Strong Fundamentals

What happened

Medtronic has delivered strong recent performance, beating the S&P 500 and prompting a raised non-GAAP EPS guidance for FY2027 after a robust Q1. Underlying operating momentum is real: cardiovascular growth, especially pulsed field ablation (PFA), continues to accelerate with significant share gains. However, the stock now trades at a premium valuation (P/E ~26.6, EV/EBITDA ~16.2) that already prices in sustained growth, leaving limited margin of safety. Key risks include the pending Applied litigation with potential trebled damages and injunction, as well as intensifying PFA competition from Abbott and Boston Scientific. While the balance sheet remains healthy with strong interest coverage and moderate leverage, the asymmetric risk profile suggests caution at current levels.

Implication

The recent price strength reflects a justified re-rating on operational improvements, but chasing the stock here offers poor risk-reward given the already rich multiple. Medtronic's free cash flow generation and healthy leverage provide downside support, yet contingent liabilities from the Applied verdict could impair cash flows and strategic flexibility. PFA growth is impressive but faces a defined competitive threat as Abbott's Volt ramps, which may pressure pricing and growth durability over the next few quarters. Near-term catalysts include the FY26 Q4 earnings (May 20, 2026) and post-trial developments in the Applied case; both could swing sentiment sharply. A disciplined approach would wait for either a pullback toward the $90 attractive entry level or confirmation that PFA share gains persist without pricing erosion.

Thesis delta

The new article highlights recent outperformance and a guidance raise, but it does not address the stock's stretched valuation or the significant litigation overhang. Our base case WAIT rating remains appropriate; the fundamental story has not materially changed, and the risks to the growth narrative (PFA competition, legal contingencies) are unchanged. No shift in thesis; we continue to view $90 as an attractive entry and $105 as a trim level.